Skip to main navigation Skip to search Skip to main content

Bleeding Associated With Antiarrhythmic Drugs in Patients With Atrial Fibrillation Using Direct Oral Anticoagulants: A Nationwide Population Cohort Study

  • Victor Chien Chia Wu
  • , Chun Li Wang
  • , Yu Chang Huang
  • , Hui Tzu Tu
  • , Yu Tung Huang
  • , Chang Fu Kuo
  • , Shao Wei Chen
  • , Kuo Chun Hung
  • , Ming Shien Wen
  • , Shang Hung Chang*
  • *Corresponding author for this work
  • Chang Gung Memorial Hospital
  • Chang Gung University
  • National Health Research Institutes Taiwan
  • University of Nottingham
  • Chang Gung University of Science and Technology

Research output: Contribution to journal › Journal Article › peer-review

11 Scopus citations

Abstract

BACKGROUND: This study investigated drug-drug interactions in patients with atrial fibrillation taking both a direct oral anticoagulant (DOAC) and an antiarrhythmic drug.

METHODS AND RESULTS: Using data from the National Health Insurance database (2012-2018), we identified 78 805 patients with atrial fibrillation on DOACs, with 24 142 taking amiodarone, 8631 taking propafenone, 2784 taking dronedarone, 297 taking flecainide, 177 taking sotalol, and 42 772 on DOACs alone. Patients with bradycardia, heart block, heart failure, mitral stenosis, prosthetic valves, or incomplete data were excluded. Propensity score matching compared those taking both DOACs and antiarrhythmic drugs with those on DOACs alone. There was an increased risk of major bleeding in patients concomitantly taking DOACs with amiodarone when compared with matched patients taking DOACs alone (hazard ratio [HR],1.13 [95% CI, 1.04-1.23]; P=0.0044), particularly in patients taking dabigatran (HR, 1.19 [95% CI, 1.03-1.38]; P=0.0175). No significant difference in bleeding risk was found for propafenone, dronedarone, flecainide, or sotalol. The small sample sizes in the flecainide and sotalol groups limit interpretation. Notably, intracranial bleeding risk was higher in patients on DOACs and amiodarone, regardless of age. Additionally, patients <80 years old taking dabigatran with amiodarone or propafenone had a higher risk of gastrointestinal bleeding.

CONCLUSIONS: Concomitant use of DOACs with amiodarone, but not dronedarone or propafenone, increases the risk of major bleeding, particularly intracranial bleeding. This study provides new evidence to guide clinicians to tailor concomitant anticoagulation and antiarrhythmic therapy for patients with atrial fibrillation.

Original languageEnglish
Article numbere033513
JournalJournal of the American Heart Association
Volume13
Issue number21
DOIs
StatePublished - 01 11 2024
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2024 The Author(s).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • antiarrhythmic drugs
  • atrial fibrillation
  • bleeding
  • DOAC
  • drug–drug interaction
  • Humans
  • Middle Aged
  • Amiodarone/adverse effects
  • Male
  • Dabigatran/adverse effects
  • Drug Interactions
  • Aged, 80 and over
  • Female
  • Retrospective Studies
  • Drug Therapy, Combination
  • Databases, Factual
  • Risk Assessment
  • Administration, Oral
  • Risk Factors
  • Dronedarone/adverse effects
  • Anticoagulants/adverse effects
  • Anti-Arrhythmia Agents/adverse effects
  • Hemorrhage/chemically induced
  • Factor Xa Inhibitors/adverse effects
  • Taiwan/epidemiology
  • Sotalol/adverse effects
  • Atrial Fibrillation/drug therapy
  • Aged

Fingerprint

Dive into the research topics of 'Bleeding Associated With Antiarrhythmic Drugs in Patients With Atrial Fibrillation Using Direct Oral Anticoagulants: A Nationwide Population Cohort Study'. Together they form a unique fingerprint.

Cite this